Stage IVA Colon Cancer Clinical Trial
Official title:
Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies
This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with bevacizumab, irinotecan hydrochloride, leucovorin calcium, and fluorouracil in treating patients with colorectal cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as irinotecan hydrochloride, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Sorafenib tosylate and bevacizumab may also block tumor growth in different ways by targeting certain cells. Giving sorafenib tosylate and bevacizumab together with combination chemotherapy may be a better treatment for colorectal cancer.
PRIMARY OBJECTIVES:
I. To determine the maximally tolerated dose of the combination of irinotecan hydrochloride,
leucovorin calcium, and fluorouracil (FOLFIRI) plus sorafenib (sorafenib tosylate) plus
bevacizumab.
SECONDARY OBJECTIVES:
I. To assess the safety of FOLFIRI plus sorafenib plus bevacizumab. II. To assess the
feasibility of the proposed combination. III. To evaluate the response rate and identify any
activity of the proposed combination.
OUTLINE: This is a dose-escalation study of sorafenib tosylate followed by a cohort study.
(Cohort study cancelled as of March 25, 2014)
Patients receive irinotecan hydrochloride intravenously (IV) over 90 minutes on day 1,
leucovorin calcium IV over 2 hours on day 1, fluorouracil IV continuously over 46 hours on
days 1-2, bevacizumab IV over 30-90 minutes on day 1, and sorafenib tosylate orally (PO)
once (QD) or twice daily (BID) on days 3-6 and 10-13*. Courses repeat every 14 days in the
absence of disease progression or unacceptable toxicity.
NOTE: *Patients may also receive sorafenib tosylate on days 7 and 14.
After completion of study therapy, patients are followed up for 3 months.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01987726 -
Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
|
||
| Terminated |
NCT01198535 -
Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
| Completed |
NCT01217450 -
Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT01637194 -
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
|
Phase 1 | |
| Completed |
NCT00005036 -
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
|
Phase 3 | |
| Completed |
NCT02393755 -
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00084643 -
GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors
|
Phase 1 | |
| Terminated |
NCT00002796 -
Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01806675 -
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
|
Phase 1/Phase 2 | |
| Completed |
NCT01643499 -
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
|
Phase 1 | |
| Withdrawn |
NCT02235324 -
Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT01802320 -
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
|
Phase 2 | |
| Terminated |
NCT01729923 -
A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
| Terminated |
NCT01320683 -
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT02728804 -
S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer
|
||
| Completed |
NCT02041481 -
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
|
Phase 1 | |
| Terminated |
NCT01365910 -
Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
|
Phase 2 | |
| Terminated |
NCT00499369 -
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
|
Phase 3 |